Abstract: PD-1/PD-L1 inhibitors are a group of immune checkpoint inhibitors as front-line treatment of multiple types of cancer. However, the serious immune-related adverse reactions limited the clinical application of PD-1/PD-L1 monoclonal antibodies, despite the promising curative effects. Therefore, it is urgent to develop novel inhibitors, such as small molecules, peptides or macrocycles, targeting the PD-1/PD-L1 axis to meet the increasing clinical demands. Our review discussed the mechanism of action of PD-1/PD-L1 inhibitors and presented clinical trials of currently approved PD-1/PD-L1 targeted drugs and the incidence of related adverse reactions, helping clinicians pay more attention to them, better formulate their intervention and resolution strategies. At last, some new inhibitors whose patent have been published are listed, which provide development ideas and judgment basis for the efficacy and safety of novel PD-1/PD-L1 inhibitors.

Keywords: PD-1, PD-L1, immune checkpoint inhibitors, clinical trials, adverse events, monoclonal antibody


中文翻译：

---

PD-1 / PD-L1抑制剂在癌症治疗中的研究现状与展望

摘要：PD-1 / PD-L1抑制剂是一组免疫检查点抑制剂，可作为多种类型癌症的一线治疗。然而，尽管有希望的疗效，严重的免疫相关不良反应限制了PD-1 / PD-L1单克隆抗体的临床应用。因此，迫切需要开发针对PD-1 / PD-L1轴的新型抑制剂，例如小分子，肽或大环化合物，以满足日益增长的临床需求。我们的综述讨论了PD-1 / PD-L1抑制剂的作用机理，并介绍了当前批准的PD-1 / PD-L1靶向药物的临床试验以及相关不良反应的发生率，有助于临床医生更加关注它们，更好地制定他们的干预和解决策略。最后，列出了一些已公开专利的新型抑制剂，

关键词： PD-1，PD-L1，免疫检查点抑制剂，临床试验，不良反应，单克隆抗体